GE Healthcare Technologies Inc (GEHC) Q1 2026 Earnings Call Transcript

Why It Matters

These results show GE Healthcare’s ability to sustain top‑line growth and improve cash conversion despite tariff pressures, positioning the firm for continued margin expansion and recurring‑revenue growth through service contracts and the IntelliRed platform.

Key Takeaways

• Revenue $5.7B, organic growth 4.8% YoY
• Record backlog $21.8B, book‑to‑bill >1
• Tariffs cut EBIT margin 200 bps, EPS down 0.7%
• IntelliRed adds $270M revenue, >30% EBITDA
• Heartbeat system reduced past‑due backlog 25% monthly

Pulse Analysis

GE Healthcare Technologies (GEHC) entered the first quarter of 2026 with a solid top‑line performance that outpaced many peers in the medical‑imaging sector. 8% organic increase driven by strong product and service sales across the United States and EMEA. 8 billion and a book‑to‑bill ratio above 1 underscore robust demand for capital equipment and multi‑year service contracts. 7% as tariff‑related costs and an unfavorable product mix eroded profitability, a pattern analysts are watching closely.

Operational discipline emerged as a counterbalance to margin pressure. The Heartbeat Business System, GEHC’s internal lean framework, accelerated order visibility and cut past‑due backlog by an average of 25% each month, translating into faster cash conversion and a free‑cash‑flow boost to $916 million. 5% on a reported basis, and the company’s enterprise agreements—now exceeding $7 billion globally—continue to embed recurring service components that enhance margin stability.

The recent IntelliRed acquisition, projected to add $270 million in revenue with EBITDA above 30%, further deepens the firm’s digital‑health and SaaS footprint. 7 billion, while flagging a cautious outlook for China amid VBP pricing pressures. The company’s mid‑single‑digit revenue target and high‑teen EBIT margin ambition signal confidence in its ability to offset tariff headwinds through cost‑optimization and higher‑margin service revenue. Investors will likely focus on the rollout of new products such as photon‑counting CT and Vivid Pioneer, as well as the integration progress of IntelliRed, to gauge whether GEHC can sustain its growth trajectory and deliver the promised margin expansion.